Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois.
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Cancer Res. 2021 May 15;81(10):2577-2583. doi: 10.1158/0008-5472.CAN-20-3337. Epub 2021 Jan 15.
Cancer metastasis is the leading cause of cancer-related mortality, and most patients with metastases from solid tumors have historically been considered incurable. Here, we discuss the evolution of our understanding of the oligometastatic state with an emphasis on the view that cancer metastasis represents a spectrum of disease. We highlight several recently published prospective clinical trials demonstrating improvements in cancer-specific outcomes with the utilization of metastasis-directed local therapies. We discuss biological aspects of oligometastases, including genetic, epigenetic, and immune determinants of the metastatic spectrum. Finally, we propose future considerations regarding clinical trial design for patients with oligometastatic disease.
癌症转移是癌症相关死亡的主要原因,大多数患有实体瘤转移的患者在历史上被认为是无法治愈的。在这里,我们讨论了对寡转移状态的理解的演变,重点是认为癌症转移代表了疾病谱的观点。我们强调了几项最近发表的前瞻性临床试验,这些试验表明,利用转移性局部治疗可以改善癌症特异性结果。我们讨论了寡转移的生物学方面,包括遗传、表观遗传和免疫决定因素。最后,我们对寡转移疾病患者临床试验设计提出了未来的考虑。